RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Start Date
4/20/2026
Completion Date
4/1/2027
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Eligibility Criteria
Age Range: 18 years to 74 years
Interventions
RE104 for Injection
Placebo
Conditions
Locations
Lighthouse Psychiatry
Gilbert, Arizona 85234
United States
Preferred Research Partners, Inc.
Little Rock, Arkansas 72211
United States
Collaborative Neuroscience Research, LLC
Garden Grove, California 92845
United States
Kadima Neuropsychiatry Institute
La Jolla, California 92037
United States
Open Mind Therapeutics
San Francisco, California 94114
United States
TRIP Clinic at Psychedelic Science Institute
Santa Monica, California 90404
United States
Innovative Clinical Research, Inc.
Lauderhill, Florida 33319
United States
University of South Florida
Tampa, Florida 33613
United States
Atlanta Center for Medical Research
Atlanta, Georgia 30331
United States
CenExel iResearch, LLC
Decatur, Georgia 30030
United States
Uptown Research Institute
Chicago, Illinois 60640
United States
Henry Ford Medical Center - Columbus
Novi, Michigan 48377
United States
Midwest Research Group
Saint Charles, Missouri 63304
United States
UNM Research Program Psychedelic Therapies
Albuquerque, New Mexico 14624
United States
NYU-H+C Clinical and Translational Science Institute
New York, New York 10016
United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio 44720
United States
Summit Headlands LLC
Portland, Oregon 97210
United States
Austin Clinical Trial Partners
Austin, Texas 78737
United States
BioBehavioral Research Austion
Austin, Texas 78759
United States
Aim Trials, LLC
Plano, Texas 75093
United States
Cedar Clinical Research
Draper, Utah 84020
United States
Inner Space State Street
Orem, Utah 84058
United States